1700001G01Rik Inhibitors
Chemical inhibitors of protein 1700001G01Rik act through various intracellular signaling pathways to inhibit its function. Staurosporine is a broad-spectrum protein kinase inhibitor, which means its inhibitory actions can prevent the phosphorylation of protein 1700001G01Rik, a process often necessary for protein activation. Similarly, LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3K), which are upstream regulators in the PI3K/AKT signaling pathway. By obstructing this pathway, they can suppress the activation signals that protein 1700001G01Rik requires for its function. Furthermore, U0126 targets the MEK enzyme in the MAPK/ERK pathway, potentially interrupting the downstream phosphorylation and activation of protein 1700001G01Rik. Rapamycin, by inhibiting the mTOR pathway, can also impede the signaling required for protein 1700001G01Rik's activity, given that mTOR is a central modulator of cell growth and proliferation, which could be linked to the protein's regulation.
The second group of inhibitors, including SB203580, SP600125, Erlotinib, and Gefitinib, target different kinases associated with stress responses, apoptosis, and growth factor signaling. SB203580 specifically inhibits p38 MAP kinase, thus potentially blocking the activation of protein 1700001G01Rik if it is involved in the p38 MAPK regulated pathway. SP600125 acts on c-Jun N-terminal kinase (JNK) and can inhibit protein 1700001G01Rik function by preventing the transmission of signals through the JNK pathway. Erlotinib and Gefitinib both act as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, which can lead to the inhibition of protein 1700001G01Rik by obstructing the EGFR signaling. PP2, as an inhibitor of Src family tyrosine kinases, can suppress the Src-related kinase activity, which may be crucial for protein 1700001G01Rik's function. Lastly, Triciribine targets the AKT signaling pathway, and by inhibiting AKT, it prevents the activation of protein 1700001G01Rik, assuming AKT pathway involvement in the protein's regulation. Each of these inhibitors, by targeting specific kinases and pathways, can impede the functional capacity of protein 1700001G01Rik, illustrating the diverse molecular interplay between kinase activity and protein regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Given that 1700001G01Rik is a protein that may be regulated by phosphorylation, staurosporine can inhibit this protein by preventing its phosphorylation, which is essential for its activation and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 can inhibit the PI3K/AKT signaling pathway, which may be crucial for the activation of 1700001G01Rik. As a result, the inhibition of this pathway leads to the functional inhibition of 1700001G01Rik by preventing its necessary activation signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, U0126 can prevent the activation of ERK, a downstream effector that could be necessary for 1700001G01Rik activation. Therefore, U0126 can inhibit the function of 1700001G01Rik by blocking its activation through the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, rapamycin can inhibit the mTOR signaling pathway, which is involved in cell growth and proliferation. As 1700001G01Rik may be regulated by or involved in mTOR signaling, rapamycin can inhibit the function of 1700001G01Rik by blocking the signaling pathway necessary for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. By inhibiting PI3K, wortmannin can inhibit the PI3K/AKT signaling pathway, leading to the functional inhibition of 1700001G01Rik by blocking its activation if it is regulated by the PI3K/AKT pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in stress responses. Inhibition of p38 MAP kinase by SB203580 can lead to inhibition of 1700001G01Rik by blocking the signaling pathway that may be required for its activation and function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). The JNK pathway is involved in stress responses and apoptosis. By inhibiting JNK, SP600125 can inhibit the function of 1700001G01Rik if it is regulated by or involved in the JNK signaling pathway, by preventing the signaling required for its activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, erlotinib can inhibit the EGFR signaling pathway. If 1700001G01Rik is regulated by or involves the EGFR signaling pathway, erlotinib can functionally inhibit the protein by blocking the necessary activation signals. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR tyrosine kinase inhibitor. It can inhibit the function of 1700001G01Rik by blocking the EGFR signaling pathway that may be required for the activation and function of the protein. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 can inhibit signaling pathways that involve Src kinases, which may be essential for the activation and function of 1700001G01Rik, leading to its functional inhibition. | ||||||